Abstract Introduction Insomnia is a common and persistent concern among breast cancer survivors, often continuing well beyond active treatment. Although Cognitive Behavioral Therapy for Insomnia (CBT-I) improves sleep continuity, the optimal dose of the intervention in oncology settings remain unclear. This study assessed the feasibility of a multi-dose CBT-I protocol and examined trajectories of sleep continuity, and adherence over the course of treatment. Methods Breast cancer survivors aged 25–85 (n=28; 78.6% White), within 6 years of completing treatment, were enrolled. Eligible participants endorsing clinically significant insomnia and fatigue (85.7% insomnia+fatigue) were randomized to one of four CBT-I dose groups (4, 8, 10, or 12 sessions). All treatment was delivered weekly via HIPAA-compliant telehealth by a CBT-I clinician. Primary outcomes included feasibility metrics: recruitment goal, n=60 0, p .001). Finally, with respect to adherence, dose did not moderate differences in groups, indicating parallel trajectories across randomized groups (all interaction p .10). Conclusion A multi-dose CBT-I protocol is feasible for breast cancer survivors. Preliminary results suggest that across all groups, participants showed statistically significant improvements in sleep continuity over time (i.e., they fell asleep faster, spent less time awake during the night, and had fewer early awakenings). However there is no effect of CBT-I dosage on adherence. Analyses are ongoing. Support (if any) 1R21CA27098701
Muench et al. (Fri,) studied this question.